Lymphatic targeting of anti-human immunodeficiency virus nucleosides pharmacokinetics of 3'-deoxy-2',3'-didehydrothymidine after intravenous and oral administration of dipalmitoyl phosphatidyl prodrug to mice

Antiviral Chemistry and Chemotherapy

Volumn 8, Issue 5, 1997, Pages 409-415

  Manouilov, K K ^a   Xu, Z S ^a   Manouilova, L S ^a   Boudinot, F D ^a   Schinazi, R F ^b   Chu, C K ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3' deoxy 2',3' didehydrothymidine; Antiviral agents; Dipalmitoylphosphatidyl d4T; Lymphatic system; Mice; Prodrug

Indexed keywords

ANTIVIRUS AGENT; DIPALMITOYLPHOSPHATIDYLCHOLINE; PRODRUG; STAVUDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG TARGETING; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE; LYMPHATIC SYSTEM; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030952546     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029700800503     Document Type: Article

References (22)

1. Anonymous (1996) Guide for the Care and Use of Laboratory Animals. Rockville: National Institutes of Health.
2. Boudinot FD, Smith SG, Funderburg ED & Schinazi RF (1991) Pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-deoxy-2′,3′-didehydrothymidine in rats. Antimicrobial Agents and Chemotherapy 35: 747-749.
3. Choi W-B, Wilson LJ, Yeola S, Liotta DC & Schinazi RF (1991) In situ complexation directs the stereochemistry of N-glycosylation in the synthesis of oxathiolanyl and dioxolanyl nucleoside analogues. Journal of the American Chemical Society 113: 9377-9379.
4. Ford Jr H, Merski CL & Kelley JA (1991) A rapid microscale method for the determination of partition cofficients by HPLC. Journal of Liquid Chromatography 14: 3365-3386.
5. Gerlowski LE & Jain RK (1983) Physiologically based pharmacokinetic modeling: principles and applications. Journal of Pharmaceutical Sciences 72: 1103-1126.
6. Hoong LK, Stange LE, Liotta DC, Koszalka GW, Burns CL & Schinazi RF (1992) Enzyme-mediated enantioselective preparation of pure enantiomers of the antiviral agent 2′,3′-dideoxy-5-fluoro-3′-thiacytidine (FTC) and related compounds. Journal of Organic Chemistry 57: 5563-5565.
7. Hosteller K, Stuhmiller LM, Lenting HBM, van den Bosch H & Richman DD (1990) Synthesis and antiretroviral activity of phospholipid analogs of azitrothymidme and other antiviral nucleosides. Journal of Biological Chemistry 265: 6112-6117.
8. Hosteller KY, Carson DC & Richman DD (1991) Phosphatidylazidothymidine: mechanism of antiviral action in CEM cells. Journal of Biological Chemistry 266: 11714-11717.
9. Hosteller KY, Richman DD, Sridhar CN, Feigner PL, Feigner J, Ricci J, Gardner MF, Selleseth DW & Ellis MN (1994) Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice. Antimicrobial Agents and Chemotherapy 38: 2792-2797.
10. Ibrahim SS, Boudinot FD, Schinazi RF & Chu CK (1996) Physicochemical properties, bioconversion and disposition of lipophilic prodrugs of 2′,3′-dideoxycytidine. Antiviral Chemistry and Chemotherapy 7: 167-172.
11. Larsen E, Kofoed T & Pedersen EP (1995) Synthesis of 2′,3′-anhydro-2′-deoxyuridines and 2′,3′-didehydro-2′,3′-dideoxyuridines using polymer supported fluoride. Synthesis Stuttgart 9: 1121-1125.
12. Manouilov KK, White CA, Boudinot FD, Fedorov II & Chu CK (1995a) Lymphatic distribution of 3′-azido-3′-deoxythymidine and 3′-azido-2′,3′-dideoxyuridine in mice. Drug Metabolism and Disposition 23: 655-658.
13. Manouilov KK, Fedorov II, Boudinot FD, White CA, Kotra LP, Schinazi RF, Hong CI & Chu CK (1995b) Lymphatic targeting of anti-HIV nucleosides: distribution of 3′-azido-3′-deoxythymidine (AZT) and 3′-azido-2′,3′-dideoxyuridine (AZdU) after administration of dipalmitoylphosphatidyl prodrugs to mice. Antiviral Chemistry and Chemotherapy 6: 230-238.
14. Manouilov KK, Xu Z-S, Boudinot FD, Schinazi RF & Chu CK (1997) Lymphatic targeting of anti-HIV nucleosides: distribution of 2′,3′-dideoxyinosine (ddI) after intravenous and oral administration of dipalmitoylphosphatidyl prodrug (DPP-ddI) in mice. Antiviral Research (in press).
15. Muranishi S (1991) Drug targeting towards the lymphatics. Advances in Drug Research 21: 1-38.
16. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP & Fauci AS (1993) HIV infection is active and progressive in lymphoid tissue during the clinical latent stage of disease. Nature 362: 355-358.
17. Rocci Jr ML & Jusko WJ (1983) LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine 16: 203-216.
18. Russell JW, Whiterock VJ, Marrero D & Kluck LJ (1990) Disposition in animals of a new anti-HIV agent: 3′-deoxy-2′,3′-didehydro-3′-deoxythymidine. Drug Metabolism and Disposition 18: 153-157.
19. Sakai A, Mori N, Shuto S & Suzuki T (1993) Deacylation-reacylation cycle: a possible absorption mechanism for the novel lymphotropic antitumor agent dipalmithoylphosphatidylfluorouridine in rats. Journal of Pharmaceutical Sciences 82: 575-578.
20. Shuto S, Itoh H, Ueda S, Imamura K & Fukukawa K (1988) A facile enzymatic synthesis of 5′-(3-Sn-phosphatidyl)nucleosides and their antileukemic activities. Chemical and Pharmaceutical Bulletin 36: 209-217.
21. Sommadossi J-P (1995) Comparision of metabolism and in vitro antiviral activity of stavudine versus other 2′,3′-dideoxynucleoside analogues. Journal of Infectious Diseases 171 (Supplement 2): 88-92.
22. Yuan J (1993) Estimation of variance for AUC in animal studies. Journal of Pharmaceutical Sciences 82: 761-763.